Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1843-1845

  Hook III, Edward W ^a,k   McCormack, William M ^b   Martin, David ^c   Jones, Robert B ^d   Bean, Karen ^e   Maroli, Allan N ^e   Handsfield, H Hunter ^f   Douglas Jr , John M ^g   Zenilman, Jonathan ^h   Leone, Peter ⁱ   Rice, Peter ^j  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e Otsuka Pharmaceuticals   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g Denver Disease Control Service   (United States)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j BOSTON MEDICAL CENTER   (United States)

^k University of Alabama at Birmingham   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; GREPAFLOXACIN; PENICILLIN DERIVATIVE; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URETHRITIS;

EID: 8544225736     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1843     Document Type: Article

References (15)

1. Bowie, W. R. 1989. Urethritis in males, p. 627-639. In K. K. Holmes, P. H. Mardh, P. F. Sparling, and P. J. Weisner (ed.). Sexually transmitted diseases, 2nd ed. McGraw-Hill International Book Co., New York, N.Y.
2. Centers for Disease Control and Prevention. 1995. 1993 sexually transmitted disease guidelines. Clin. Infect. Dis. 20(Suppl. 1):1S-109S.
3. Cook, P. J., J. M. Andrews, R. Wise, D. Honeybourne, and H. Moudgil. 1995. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35:317-326.
4. Fox, K. K., J. S. Knapp, K. K. Holmes, E. W. Hook III, F. N. Judson, S. E. Thompson, J. A. Washington, and W. L. Whittington. Antimicrobial resistance in Neisseria gonorrhoeae in the United States 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones. J. Infect. Dis., in press.
5. Hook, E. W., III, and H. H. Handsfield. 1989. Gonococcal infections in the adult, p. 149-165. In K. K. Holmes, P. H. Mardh, P. F. Sparling, and P. J. Weisner (ed.), Sexually transmitted diseases, 2nd ed. McGraw-Hill International Book Co., New York, N.Y.
6. Kimura, M., T. Kishimoto, Y. Niki, and R. Soejima. 1993. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob. Agents Chemother. 37:801-803.
7. Moran, J. S., and W. C. Levine. 1995. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin. Infect. Dis. 20(Suppl. 1):S47-S65.
8. Morello, J. A., W. M. Janda, and G. V. Doern. 1991. Neisseria and Branhamella, p. 258-276. In A. Balows, W. J. Hausler, Jr., K. L. Herrman, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
9. National Committee for Clinical Laboratory Standards. 1990. Approved standard M7-A2. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. National Committee for Clinical Laboratory Standards, Villanova, Pa.
10. O'Callaghan, C. H., A. Morris, S. M. Kirby, and A. H. Shingler. 1972. Novel method for detection of β-lactamase by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1:283-288.
11. Pitlick, W., A. Hutson, P. Lohse, D. Malone, and J. Cabana. 1991. The pharmacokinetics of OPC-17116, a new quinolone antibiotic, following multiple doses, abstr. 1484. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Ridgway, G. L. 1995. Quinolones in sexually transmitted diseases. Global experience. Drugs 49(Suppl. 2):S115-S122.
13. Takahashi, Y., Y. Itoh, T. Doi, M. Kuriyama, and Y. Kawada. 1991. Penetration of OPC-17116, a new quinolone compound, into male genital tracts and its in vitro antibacterial activity, abstr. 1486. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
14. Wise, R., J. M. Andrews, and N. Brenwald. 1993. The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J. Antimicrob. Chemother. 31:497-504.
15. Zenilman, J. M., T. Neumann, M. Patton, and C. Reichart. 1993. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 37:2244-2246.